Neuroendocrine neoplasms represent a rare, diverse spectrum of malignancies arising from neuroendocrine cells throughout the body. Clinicians frequently encounter these challenging tumors within the gastrointestinal tract and the pancreas. Understanding immune checkpoint pathways in digestive neuroendocrine neoplasms is crucial for developing novel targeted immunotherapies. Recently, researchers conducted a comprehensive systematic review and meta-analysis evaluating programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) expression across digestive neuroendocrine neoplasms. By evaluating data from 29 distinct studies comprising 2,633 patients, the study clarified how these biomarkers correlate with tumor differentiation, primary anatomical location, and overall survival. Consequently, these findings offer essential guidance for oncologists and pathologists seeking to risk-stratify patients and identify candidates for targeted immunotherapy.

PD-L1 Expression in Digestive Neuroendocrine Neoplasms

Programmed death-ligand 1 functions as a major coinhibitory molecule that suppresses T-cell mediated antitumor immunity. In various gastrointestinal malignancies, elevated PD-L1 expression facilitates immune evasion and promotes aggressive tumor progression. However, the precise clinical significance of PD-L1 expression in digestive neuroendocrine neoplasms has historically remained controversial due to small sample sizes in individual studies. The updated meta-analysis systematically pooled international evidence to establish definitive correlations. The comprehensive data revealed that PD-L1 expression varies substantially based on the biological behavior and primary site of the tumor. In contrast, programmed cell death protein 1 (PD-1) expression showed no statistically significant association with clinicopathological features or patient outcomes. Therefore, PD-L1 represents a more specific diagnostic and prognostic indicator than PD-1 in these malignancies. Pathologists frequently assess PD-L1 expression via immunohistochemistry using validated scoring systems such as the tumor proportion score or combined positive score. Consequently, standardized biomarker assessment helps clinicians understand tumor immunogenicity. Moreover, identifying PD-L1 positivity provides valuable insight into the surrounding microenvironment, where active immune evasion occurs. Thus, routine profiling of PD-L1 expression may soon become standard practice during baseline pathology evaluation.

Correlation with Tumor Grade and Anatomical Location

The meta-analysis established a robust correlation between PD-L1 expression and aggressive tumor biology. Specifically, tumors displaying PD-L1 positivity were significantly more likely to present with a high histological grade. High-grade neuroendocrine neoplasms and poorly differentiated neuroendocrine carcinomas frequently exhibit elevated proliferation rates, marked genomic instability, and enhanced immune cell infiltration. Consequently, these aggressive biological features stimulate the upregulation of PD-L1 on tumor and stromal cells. Furthermore, primary tumor location plays an important role in biomarker distribution. The meta-analysis revealed that pancreatic neuroendocrine neoplasms are significantly more likely to express PD-L1 compared to other primary sites. This site-specific distinction suggests that the pancreatic tumor microenvironment harbors unique inflammatory signaling pathways that drive checkpoint expression. In contrast, well-differentiated indolent tumors located in the small bowel or appendix demonstrate considerably lower PD-L1 levels. Therefore, clinicians must interpret biomarker status in the context of both histological differentiation and anatomical origin. Understanding these relationships enables multidisciplinary oncology teams to refine diagnostic stratification and tailor monitoring protocols effectively for high-risk patients.

Divergent Prognostic Implications Across Tumor Subtypes

The prognostic influence of PD-L1 expression varies markedly depending on the anatomical origin of the neoplasm. In patients with gastroenteropancreatic neuroendocrine neoplasms, positive PD-L1 expression strongly correlates with inferior overall survival. This association reflects the aggressive phenotype and immunosuppressive microenvironment typical of PD-L1-positive gastroenteropancreatic tumors. Consequently, PD-L1 positivity serves as an independent marker of poor prognosis in pancreatic and lower gastrointestinal lesions. In striking contrast, positive PD-L1 expression in esophageal neuroendocrine neoplasms was associated with significantly improved overall survival. This paradoxical finding suggests that PD-L1 expression in the esophagus might represent an active, pre-existing host antitumor immune response rather than immune exhaustion. Esophageal neuroendocrine carcinomas often exhibit high mutational burdens and brisk lymphocytic infiltration, where PD-L1 upregulation reflects interferon-gamma release from functional cytotoxic T cells. Therefore, immune checkpoint pathways exert divergent biological effects across different segments of the digestive tract. Oncologists must avoid applying uniform prognostic assumptions across heterogeneous neuroendocrine subtypes, recognizing instead that anatomical tissue context fundamentally modulates immune dynamics.

Therapeutic Potential of Immune Checkpoint Inhibitors

The definitive demonstration of PD-L1 expression in aggressive neuroendocrine tumors provides a strong scientific rationale for immunotherapy. Currently, standard therapeutic options for advanced or poorly differentiated digestive neuroendocrine carcinomas remain limited, primarily relying on cytotoxic platinum-based regimens. However, response durations to conventional chemotherapy are often brief, and recurrent disease progresses rapidly. Immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies, offer a promising alternative for restoring T-cell mediated tumor destruction. Because PD-L1 expression correlates with high tumor grade, patients with grade 3 neuroendocrine neoplasms or neuroendocrine carcinomas may derive substantial benefit from checkpoint blockade. Additionally, combining immune checkpoint inhibitors with anti-angiogenic agents or cytotoxic chemotherapy may produce synergistic antitumor effects by disrupting the immunosuppressive stroma. Several ongoing phase II and III clinical trials are actively investigating dual checkpoint inhibition and combination regimens in advanced neuroendocrine neoplasms. Consequently, establishing baseline PD-L1 positivity helps clinicians identify optimal candidates for experimental immunotherapy trials. Nevertheless, clinicians require robust prospective clinical trial data before universally incorporating checkpoint inhibitors into routine standard practice.

Clinical Challenges and Future Diagnostic Directions

Despite promising insights, several diagnostic and therapeutic challenges persist in clinical management. First, significant heterogeneity exists across different immunohistochemical assays, antibody clones, and scoring algorithms used to evaluate PD-L1 expression. Variations between the tumor proportion score and combined positive score can lead to discordant classifications across clinical laboratories. Therefore, international pathology societies must establish standardized cutoff values tailored specifically to neuroendocrine malignancies. Second, tumor spatial and temporal heterogeneity remains a substantial hurdle, as primary tumors and distant metastases may express divergent PD-L1 levels. Biopsy timing and tissue preservation techniques also influence biomarker stability. Moreover, relying solely on PD-L1 status may not completely predict immunotherapy response, indicating the need for multi-omic biomarker panels. Future diagnostic strategies should integrate PD-L1 expression with tumor mutational burden, microsatellite instability status, and gene expression profiling. By combining these complementary modalities, clinicians can achieve precise immunophenotyping and predict treatment outcomes more accurately. Ultimately, large-scale prospective clinical trials will validate these biomarkers and pave the way for individualized immunotherapy strategies in neuroendocrine oncology.

Frequently Asked Questions

How does PD-L1 expression affect prognosis in gastroenteropancreatic NENs?

In gastroenteropancreatic neuroendocrine neoplasms, positive PD-L1 expression significantly correlates with worse overall survival. It reflects an immunosuppressive tumor microenvironment and higher histological grade. Patients with PD-L1-positive tumors face an increased risk of disease progression and shorter survival compared to PD-L1-negative individuals. Consequently, oncologists utilize PD-L1 expression as an adverse prognostic biomarker to identify high-risk patients who need intensive disease monitoring and tailored therapeutic interventions.

Why does PD-L1 positivity correlate with better survival in esophageal NENs?

In esophageal neuroendocrine neoplasms, positive PD-L1 expression correlates with improved overall survival. This favorable outcome likely occurs because PD-L1 upregulation in the esophagus indicates an active host antitumor immune response. When cytotoxic T lymphocytes vigorously infiltrate the tumor, they secrete interferon-gamma, which triggers adaptive PD-L1 expression. Therefore, PD-L1 positivity in this specific anatomical context reflects robust pre-existing immune engagement rather than terminal immune exhaustion.

What is the role of PD-1 expression in digestive neuroendocrine tumors?

Unlike PD-L1, programmed cell death protein 1 (PD-1) expression showed no statistically significant association with clinicopathological features, tumor grade, or overall survival in digestive neuroendocrine neoplasms. While PD-1 is expressed on tumor-infiltrating lymphocytes, its isolated measurement provides limited prognostic utility across gastrointestinal sites. Therefore, current evidence identifies PD-L1, rather than PD-1, as the primary clinicopathological biomarker and therapeutic indicator in digestive neuroendocrine malignancies.

Disclaimer: This content is for informational and educational purposes only and is intended exclusively for healthcare professionals. It should not be used as a substitute for professional medical judgment, diagnosis, or treatment. Medical knowledge evolves rapidly, and while efforts are made to ensure accuracy, clinical decisions must rely on individualized patient assessment, updated manufacturer instructions, and applicable clinical guidelines. The authors and publishers assume no liability for any injury, loss, or adverse outcomes resulting from the use of this information. Refer to the latest local and national guidelines for clinical practice.

References

1. Zheng Q et al. Association between PD-1/PD-L1 Expression and Clinicopathological Parameters as well as Prognosis in Neuroendocrine Neoplasms of the Digestive System: A Systematic Review and Meta-Analysis. Endocr Relat Cancer. 2026 Aug 24. doi: undefined. PMID: 42636443.
2. Ali AS, Langer SW, Federspiel B, et al. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS ONE. 2020;15(12):e0243900.
3. Kim C, Kim B, Kang G, et al. Correlation between PD-L1 expression and clinical pathology, immunobiological markers, and prognosis in gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis. Front Oncol. 2022;12:897534.